Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)

The conclusion of the Expert Council reports an agreement on the place of the P2Y12 receptor blocker prasugrel in the early invasive treatment of patients with acute coronary syndrome ACS, according to the results of the multicenter randomized controlled study ISAR-REACT 5. Prasugrel should be consi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: S. N. Tereshchenko, M. G. Glezer, S. A. Abugov, O. V. Averkov, S. I. Antipov, A. S. Galyavich, M. Yu. Gilyarov, D. V. Duplyakov, A. A. Efremushkina, D. A. Zateyshchikov, V. V. Ivanenko, E. D. Kosmacheva, O. V. Krestyaninov, Yu. M. Lopatin, E. P. Panchenko, V. V. Ryabov, E. V. Samokhvalov, I. I. Staroverov, S. A. Ustyugov, A. V. Khripun, S. V. Shalaev, R. M. Shakhnovich, I. S. Yavelov, A. N. Yakovlev, S. S. Yakushin
Formaat: Artigo
Taal:Russo
Gepubliceerd in: «FIRMA «SILICEA» LLC 2019-11-01
Reeks:Российский кардиологический журнал
Onderwerpen:
acute coronary syndrome
prasugrel
p2y12 receptor blocker
Online toegang:https://russjcardiol.elpub.ru/jour/article/view/3640
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items